, DAP-kinase, ECadherin, and RASSF1A genes using methylationspeci®c PCR (MSP) in 80 patients. The prevalence of p16 INK4a , DAP-kinase, E-Cadherin, and RASSF1A promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), 6/80 (7.5%) respectively. In 48 cases (60%), at least one of these promoters was methylated. There was a signi®cant association of methylation of any of these genes and ever smoking (P=0.006). p16
INK4a gene promoter methylation was associated with a younger age of smoking initiation (P50.03); E-Cadherin promoter methylation was associated with an increased number of pack years smoked (P50.03). We also found an association of methylation of any gene and T status (OR=2.7, P50.05). Tumors with p16
INK4a methylation were signi®cantly less likely to show lymph node metastasis (P50.001). DAP-kinase promoter methylation was signi®cantly associated with lymph node metastasis and this relationship was dependent upon p16
INK4a promoter methylation status. Our results suggest that, in HNSCC, promoter methylation of these four genes accumulates with increasing tumor size. This may re¯ect distinct pathways of somatic inactivation leading to cancer; additional larger studies are needed to further investigate this possibility. Tobacco smoking may play an important role in both the occurrence of promoter methylation as well as delineating the precise pathway that eventually results in a tumorigenic phenotype.
Introduction
DNA methylation is essential for normal dierentiation and development (Brandeis et al., 1993; Li et al., 1992) and aberrant DNA promoter methylation is a common feature of many human cancers Esteller et al., 2001) . Recent work has demonstrated that the epigenetic transcriptional silencing by promoter methylation of tumor suppressor genes in HNSCC is a relatively common and important feature of this disease (Esteller et al., 2001; Reed et al., 1996; Sanchez-Cespedes et al., 2000; Riese et al., 1999) . However, the mechanism responsible for methylating important somatic loci has not been elucidated.
Head and neck cancer, like lung cancer, is primarily associated with chronic tobacco carcinogen exposure (Blot et al., 1988) . Exposure to alcoholic beverages interacts with the eects of tobacco use to enhance head and neck cancer risk (Saracci, 1987) . There is also evidence that diet, smokeless tobacco use, mouthwash use, and human papilloma virus infection play a role in the genesis of HNSCC (Spitz and Trizna, 1999) . In addition, there may be an ordered progression (beginning with premalignant leukoplakia) involving the alteration of several genetic pathways in the development of HNSCC . However, the precise mechanism by which tobacco, alcohol and these other exposures act to induce the alterations of normally functional genes remains unknown. The patterns of exposure to carcinogens may contribute variously to this process, selecting distinct genes in these causal pathways for somatic inactivation based upon characteristics that are epidemiologically discernable. Hence, we have hypothesized that the precise patterns of epigenetic inactivation of important genes in the causal pathway for genesis of HNSCC may re¯ect important similarities or dierences related to the mechanism of gene inactivation in each patient.
The inactivation of the p16
INK4a gene is common in HNSCC and plays an important role in tumor development (Esteller et al., 2001; Reed et al., 1996; Sanchez-Cespedes et al., 2000; Riese et al., 1999; Nagai, 1999) . We have previously shown that tobacco carcinogen exposure is associated with methylation of the p16
INK4a gene in lung cancer (Kim et al., 2001a) . At the same time, no association of smoking and methylation silencing of another gene, the DAP-kinase gene, was observed in the same group of lung cancer patients (Kim et al., 2001b) . p16
INK4a regulates the RB pathway, leading to inhibition of cell cycle progression in the G1-S transition (Serrano et al., 1993) . DAPkinase (Death Associated Protein Kinase) also plays a critical role in tumor development via the p19ARF/p53 pathway (Raveh et al., 2001) . Sanchez-Cespedes et al. (2000) demonstrated the correlation between the presence of DAP-kinase methylation and lymph node involvement and advanced disease stage in HNSCC. ECadherin, a Ca 2+ -dependent, homotypic cell to cell adhesion molecule, suppresses tumor cell invasion and metastasis in experimental tumor models (Vleminckx et al., 1991; Frixen et al., 1991; Navarro et al., 1991) . Hypermethylation of E-cadherin is relatively common in human cancers Gra et al., 1995) . The down-regulation of E-Cadherin expression has been associated with de-dierentiation and lymph node metastasis in HNSCC (Schipper et al., 1991) . In HNSCC, ras gene mutations have been identi®ed in less than 5% of patients (Yarbrough et al., 1994) . Dammann et al. (2000) , reported recently that RASSF1A, maps to 3p21.31, acts as tumor suppressor and may function in a ras signaling pathway or related pathway. Finally, HNSCC shows prominent LOH of 3p (Kok et al., 1997; Maestro et al., 1993) , and promoter methylation of RASSF1A gene is common in lung, breast, and renal cell carcinoma (Dammann et al., 2000 (Dammann et al., , 2001a Morrissey et al., 2001) .
We collected freshly resected surgical specimens from 80 HNSCC patients in the Longwood Medical Area of Boston to determine the prevalence of methylation of the p16
INK4a , DAP-kinase, RASSF1A and E-Cadherin genes, examining associations of methylation with tobacco smoking, alcohol intake, gender, age and characteristics of the tumor.
Results
The prevalence of p16
INK4a
, DAP-kinase, and ECadherin promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), respectively. The prevalence of RASSF1A methylation was 6/80 (7.5%). In 48 (60%) cases, at least one of the p16
INK4a , DAP-kinase, E-Cadherin or RASSF1A promoters was methylated. Table 1 summarizes the relationship of the methylation status of the promoters of the four genes studied and the clinical (and pathological) characteristics of the patients with HNSCC. Gender, age, tumor location, clinical stage, and grade were not associated with the promoter methylation status of the genes when all the genes were examined together. Methylation, when taken as a single variable, was associated with a larger tumor size (T=0.1 compared with T=2, 3 or 4); the adjusted odds ratio for the association of methylation of any gene promoter with this dichotomous measure was 2.7 (95%CI=1.1 ± 7.1). Smoking status, measured as`never',`former' or`current', was signi®cantly associated with the same measure of promoter methylation (P=0.006, Table 2 ). The mean value for pack years and packs per day was higher in patients whose tumors showed some methylation. The mean age at which patients started smoking was lower in those with methylation; however, this was not statistically signi®cant. Methylation of any promoter was not associated with alcohol consumption (data not shown).
The relationship of promoter methylation of the p16
INK4a and E-Cadherin genes and tobacco carcinogen exposure is shown in Tables 3 and 4 . There was a signi®cant association of methylation of the p16
promoter and age at starting smoking (P50.03). The number of pack years smoked was also associated with methylation of E-Cadherin promoter (P50.03). The adjusted odds ratio for p16
INK4a methylation increased in proportion to pack years smoked. RASSF1A and DAP-kinase promoter methylation were not associated with any measure of tobacco smoking.
When the clinical parameters of the tumors were examined, p16
INK4a gene promoter methylation was inversely associated with lymph node involvement (Table 5) . Controlling for age and sex, p16
INK4a methylation was signi®cantly associated with a decreased likelihood of regional metastatic disease at surgery (P50.001). Methylation of the other gene promoters was not signi®cantly associated with stage, T, or N status (data not shown). DAP-kinase methylation, which has previously been associated with metastatic disease and higher stage in head and neck cancer, was not signi®cantly associated with stage in the overall data. However, when we strati®ed the data based upon p16
INK4a methylation status, among the p16
INK4a unmethylated tumors there were nine that showed DAP-kinase methylation and 45 that did not have DAP-kinase promoter methylation (Table 6 ). All nine had an advanced N status of 2 or 3 (P=0.004).
There was a borderline signi®cant association of increased years of drinking with methylation of the ECadherin promoter (P50.07, Table 4 ). There was the suggestion of more p16
INK4a promoter methylation in patients who reported more drinks per day, but this was not statistically signi®cant (data not shown). Tobacco use and alcohol consumption were not associated with RASSF1A or DAP-kinase promoter methylation (data not shown).
Discussion
Methylation of multiple genes has been observed in HNSCC. The frequency of p16
INK4a and DAP-kinase
Promoter methylation in HNSCC M Hasegawa et al promoter methylation has been reported to range from 21 ± 47% (Reed et al., 1996; Sanchez-Cespedes et al., 2000; Riese et al., 1999; Esteller et al., 1999; Rosas et al., 2001) , and 18 ± 33% (Sanchez-Cespedes et al., 2000; Esteller et al., 1999; Rosas et al., 2001) respectively; this is consistent with the prevalence of promoter methylation reported here. The prevalence of promoter methylation of the E-Cadherin gene was 36.3% in our study; to our knowledge this has not previously been reported for HNSCC. In addition, we observed the prevalence of RASSF1A promoter methylation to be quite low (7.5%). RASSF1A has been found to be hypermethylated in approximately 34 ± 63% (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001 ) of primary non-small cell lung cancers (NSCLCs), 72 ± 79% of primary small cell lung cancers Dammann et al., 2001b) , 62% of breast cancers (Dammann et al., 2001a) , and 23 ± 56% (Morrissey et al., 2001; Yoon et al., 2001 ) of primary renal cell carcinomas (RCCs). Interestingly, Lo et al. (2001) have reported 14 of 21 RCCs, primary nasopharyngeal carcinomas to show RASSF1A promoter methylation. This dierence in the prevalence of RASSF1A promoter methylation may re¯ect the known dierences in this disease (the epidemiology and histology dier) or it may re¯ect the fact that the pathway leading to these diseases is quite dierent. Alternatively, the extent of methylation of the promoter may dier and the dierent primers used might simply re¯ect this; this is unlikely in that mapping studies suggest much of the promoter is uniformly methylated (Lo et al., 2001) . Several recent studies have reported an association between smoking and gene promoter methylation in lung cancer (Kim et al., 2001a; Eguchi et al., 1997; Zochbauer-Muller et al., 2001) . P16
INK4A methylation is strongly associated with tobacco smoking in nonsmall cell lung carcinoma (NSCLC) (Kim et al., 2001a . Kim et al. (2001a) reported that p16
INK4a methylation was linearly associated with duration of smoking. Our data in HNSCC also suggest that p16
INK4a promoter methylation is related to tobacco smoking. Interestingly, we found a signi®cant association of p16
INK4a promoter methylation and younger age of smoking initiation in HNSCC. This supports other studies that suggest p16
INK4a methylation to be an early event in solid tumors that can be detected in precursor lesions, or dysplasia (Nagai, 1999; Belinsky et al., 1998) .
We also found that E-Cadherin gene promoter methylation was associated with increased pack years smoked in HNSCC. In in vitro studies, de novo methylation of E-Cadherin CpG sites expands progressively with time, reaching a maximum at late passages (Gra et al., 1997) . This is consistent with the maximum amount of methylation arising late in the evolution of the tumor. We found methylation of the p16
INK4a
and E-Cadherin genes to be strongly associated with smoking exposure (early initiation or intensity of smoking). In both instances this may predominantly re¯ect the fact that increasing tobacco carcinogen exposure among cases in a case series (i.e. in the absence of controls) is a surrogate for a relative genotoxin`resistant' phenotype. That is, the association of promoter methylation with increasing exposure to tobacco carcinogens exposure among cases may indicate that these individuals, relative to others with the same disease, have cells relatively resistant to gene alteration induced via a genotoxic means (i.e. mutation). It is known that tobacco smoke is very toxic and will induce signi®cant cell death in the respiratory tract. This, in turn, will give rise to both increased smoking-associated genotoxic damage and cell turnover. The fact that increased smoking is associated with gene promoter methylation rather than gene deletion or mutation suggests that the enhanced cell turnover and increased cell division is perhaps the driving carcinogenic force in these selected patients. At the same time, there was no association of DAP-kinase and RASSF1A gene promoter methylation and smoking. Kim et al. (2001a) also reported that tobacco carcinogen exposure is associated with methylation of the p16
INK4a gene in lung cancer with no association of smoking and methylation of the DAP-kinase gene was observed in the same group of lung cancer patients (Kim et al., 2001b) . Like lung cancer, this suggests that tobacco exposure can aect DNA hypermethylation in a gene speci®c manner in HNSCC. The fact that we only observed a signi®cant relationship of DAP-kinase methylation and lymph node involvement in p16 INK4a unmethylated cases is consistent with p16
INK4a methylation being an early event and suggests that there may be distinct pathways involved in DAP-kinase methylation.
The mechanism responsible for the induction of gene promoter methylation remains obscure. Previous works have reported that the activity of DNA-methyltransferase may increase in neoplastic cells Belinsky et al., 1995) and that there may be a protective mechanism that isolates some CpG islands on a cell type-and gene-speci®c basis, making them less available for methylation Gra et al., 1997; Jost, 1993) . Tobacco exposure may induce, directly or indirectly, damage to speci®c CpG islands, abrogating protective mechanisms, or perhaps may induce the DNA methyltransferase. Another possible INK4a or E-Cadherin) by promoter inactivation will be more likely. Tobacco smoking could then act simply to enhance the likelihood of division and thereby be associated with methylation of genes that are important in clonal selection.
Methylated tumor suppressor alleles retain the wild type DNA sequence and, as a result, oer novel targets for therapy. The reversal of the epigenetic silencing could re-activate the normal transcriptional mechanism and allow production of normal proteins that might induce the regression of the malignant phenotype. Further understanding of the determinants of promoter methylation of speci®c genes may oer insight into the mechanism responsible for its induction; this may also provide critical clues for reversing this phenotype.
In conclusion, we demonstrate that tobacco smoking may play an important role in promoter methylation and early initiation and increased intensity of smoking exposure may aect the promoter methylation in a gene speci®c manner in HNSCC. Additional work is needed to clarify the mechanism(s) responsible for these observations. Information on smoking history, alcohol consumption, as well as other demographic characteristics were elicited in questionnaires that were reviewed by a trained interviewer at the time of treatment or were obtained from medical chart review.
Materials and methods

Sample collection and study population
DNA extraction and sodium bisulfite modification DNA was extracted from fresh-frozen tissue using QIAamp DNA Mini kit (QIAGEN) according to the manufacture's protocol. Sodium bisul®te modi®cation was performed as described (Kim et al., 2001a ,b, Herman et al., 1996 . In brief, 1 mg of extracted DNA (50 ml) was denatured in 0.2 M NaOH for 15 min at 378C. Thirty ml of 10 mM hydroquinone (Sigma) and 520 ml of 3 M sodium bisul®te (Sigma) at pH 5.0, both freshly prepared, were added and samples were incubated at 508C for 16 h. Modi®ed DNA was puri®ed with Wizard DNA clean up System (Promega) according to the manufacture's instruction. Modi®cation was completed by addition of 0.3 M NaOH for 15 min at room temperature. EtOH precipitation was done with 2.5 M ammonium acetate and modi®ed DNA was dissolved in 40 ml of autoclaved distilled water and modi®ed DNA was stored at 7708C until use.
Methylation specific PCR
Methylation status of the promoter region was determined by Methylation-Speci®c PCR (MSP). MSP for p16
INK4a (Kim et al., 2001a; Esteller et al., 1999; Herman et al., 1996) , DAPkinase (Kim et al., 2001b; Esteller et al., 1999) and ECadherin (Herman et al., 1996) were performed as described previously. A bisul®te genomic sequence of RASSF1A was modi®ed from GenBank Accession No. AC002481 (Dammann et al., 2000) . Methylation speci®c and unmethylated speci®c primers were designed at CpG sites of the promoter region previously described by Dammann et al. (2000) . The RASSF1A methylated sense primer was 5'-TTCGTC-GTTTAGTTTGGATTTTG (antisense 5'-CCGATTAAA-CCCGTACTTCG) and the unmethylated sense primer was 5'-TGTTGTTTAGTTTGGATTTTGG (antisense 5'-TACA-ACCCTTCCCAACACAC).
The PCR reaction mixture included 50 ng modi®ed DNA as a template, 16PCR buer II (Applied Biosystems), 0.2 mM of dNTPs, 0.5 mM of primers, 1.5 mM of MgCl 2 , 1.25 units of AmpliTaq Gold (Applied Biosystems) in total volume of 50 ml.
PCR ampli®cation was performed as follow: 958C for 10 min and then 35 cycles of 958C for 30 s, 568C for 30 s, 728C for 30 s, and a ®nal extension of 8 min at 728C. PCR products were loaded onto 2.5% Agarose gel in 16 TrisBorate EDTA buer and stained by ethidium bromide.
Statistical analysis
Data were analysed using SAS software. In univariate analysis, the Chi-square test or Fisher exact test was used for categorical variables and the Wilcoxon rank sum test was used for the comparison of continuous variables. Adjusted odds ratios (OR) and 95% con®dence intervals (CI) were obtained using unconditional logistic regression. All tests of signi®cance were two-sided.
